- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
- eFFECTOR Therapeutics Announces Reverse Stock Split
- eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
- eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
More ▼
Key statistics
On Friday, eFFECTOR Therapeutics Inc (EFTR:NAQ) closed at 2.20, 37.50% above the 52 week low of 1.60 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.12 |
---|---|
High | 2.29 |
Low | 2.12 |
Bid | 2.10 |
Offer | 2.20 |
Previous close | 2.16 |
Average volume | 151.15k |
---|---|
Shares outstanding | 4.70m |
Free float | 4.57m |
P/E (TTM) | -- |
Market cap | 10.35m USD |
EPS (TTM) | -17.11 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼